SCHEMBL4398615

SCHEMBL4398615

CCOC(=O)CSc1cccs1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
KMT2A Q03164 5/20 0.54
MAPT P10636 4/20 0.54
MEN1 O00255 4/20 0.54
LMNA P02545 3/20 0.54
NPSR1 Q6W5P4 2/20 0.54
PPARG P37231 1/20 0.54
NCOA2 Q15596 1/20 0.54
NCOA1 Q15788 1/20 0.54
NCOA3 Q9Y6Q9 1/20 0.54
HPGD P15428 6/20 0.51
HSD17B10 Q99714 4/20 0.51
TSHR P16473 3/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
ALOX15 P16050 1/20 0.50
CLK1 P49759 1/20 0.50
RXFP1 Q9HBX9 1/20 0.48
CCNB2 O95067 1/20 0.47
CCNE2 O96020 1/20 0.47
CDK1 P06493 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11736051 0.85 L3MBTL1 (0.54) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL6703333 0.83 KMT2A (0.53) ALDH1A1KMT2AMAPTMEN1HPGD
SCHEMBL11171960 0.83 L3MBTL1 (0.49) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL6278646 0.81 PTGDR2 (0.46) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL6285438 0.80 PTGDR2 (0.47) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL8316805 0.79 CCNB2 (0.48) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL1121674 0.78 NPC1 (0.53) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL9582167 0.76 PTGER1 (0.39) ALDH1A1KMT2AMAPTMEN1LMNA
SCHEMBL2213224 0.75 HPGD (0.56) ALDH1A1KMT2AMAPTMEN1NPSR1
SCHEMBL8639480 0.75 NPC1 (0.50) ALDH1A1KMT2AMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111808003-A Preparation method of thioether 甘肃农业大学 2020-10-23 CN disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed
EP-1051176-A4 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARM PROD INC (US) 2002-06-12 EP disclosed
EP-1208097-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS Aventis Pharmaceuticals Inc. (US) 2002-05-29 EP disclosed
WO-2001007436-A2 SUBSTITUTED OXOAZAHETEROCYCLYL COMPOUNDS AVENTIS PHARMACEUTICALS INC. (US) 2001-02-01 WO disclosed
EP-1051176-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS Aventis Pharmaceuticals Products Inc. (US) 2000-11-15 EP disclosed
WO-2000032590-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 2000-06-08 WO disclosed
WO-1999037304-A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 ALDH1A1 3776/4885KMT2A 2513/4885MAPT 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.